Edge Therapeutics (EDGE) Lifted to Buy at BidaskClub

BidaskClub upgraded shares of Edge Therapeutics (NASDAQ:EDGE) from a hold rating to a buy rating in a research note released on Monday, February 5th.

Several other equities analysts have also recently issued reports on EDGE. Credit Suisse Group reiterated an outperform rating and set a $17.00 price target on shares of Edge Therapeutics in a research report on Thursday, January 18th. Zacks Investment Research cut Edge Therapeutics from a buy rating to a hold rating in a report on Wednesday, January 3rd. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Edge Therapeutics has a consensus rating of Buy and a consensus target price of $20.00.

Shares of Edge Therapeutics (EDGE) opened at $13.61 on Monday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 8.34 and a current ratio of 8.34. The firm has a market capitalization of $409.19, a price-to-earnings ratio of -8.72 and a beta of 3.32. Edge Therapeutics has a 12 month low of $7.30 and a 12 month high of $13.98.

In other Edge Therapeutics news, insider Brian A. Leuthner sold 7,500 shares of the business’s stock in a transaction dated Tuesday, December 5th. The stock was sold at an average price of $9.86, for a total value of $73,950.00. Following the completion of the sale, the insider now owns 95,236 shares of the company’s stock, valued at $939,026.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Brian A. Leuthner sold 2,500 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $13.14, for a total value of $32,850.00. Following the completion of the sale, the chief executive officer now directly owns 82,736 shares of the company’s stock, valued at approximately $1,087,151.04. The disclosure for this sale can be found here. In the last three months, insiders have sold 20,861 shares of company stock valued at $215,760. Insiders own 36.19% of the company’s stock.

Several institutional investors have recently bought and sold shares of EDGE. Janus Henderson Group PLC bought a new position in shares of Edge Therapeutics in the second quarter worth about $21,962,000. JPMorgan Chase & Co. increased its stake in Edge Therapeutics by 223.4% during the third quarter. JPMorgan Chase & Co. now owns 379,075 shares of the biotechnology company’s stock valued at $4,063,000 after acquiring an additional 261,850 shares during the period. Sphera Funds Management LTD. increased its stake in Edge Therapeutics by 122.5% during the third quarter. Sphera Funds Management LTD. now owns 333,737 shares of the biotechnology company’s stock valued at $3,581,000 after acquiring an additional 183,737 shares during the period. State Street Corp increased its stake in Edge Therapeutics by 16.3% during the second quarter. State Street Corp now owns 277,352 shares of the biotechnology company’s stock valued at $2,847,000 after acquiring an additional 38,909 shares during the period. Finally, Goldman Sachs Group Inc. bought a new position in Edge Therapeutics during the second quarter valued at about $374,000. Institutional investors and hedge funds own 50.31% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/14/edge-therapeutics-edge-stock-rating-upgraded-by-bidaskclub.html.

Edge Therapeutics Company Profile

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply